clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Owen RJ | Helicobacter pylori resists arrest. | 1999 | Gut | pmid:10075942 |
| Marais A et al. | Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. | 1999 | Gut | pmid:10075951 |
| de Jong JJ et al. | Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient. | 1999 | Transpl. Int. | pmid:10080410 |
| Ramirez J et al. | Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. | 1999 | Clin Ther | pmid:10090428 |
| Talley NJ et al. | Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. | 1999 | BMJ | pmid:10092259 |
| Khoo KH et al. | Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex. | 1999 | J. Biol. Chem. | pmid:10092667 |
| Iwasaki A | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. | 1999 | Nippon Rinsho | pmid:10036949 |
| Habu Y et al. | [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease]. | 1999 | Nippon Rinsho | pmid:10036950 |
| Shirai T et al. | [Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer]. | 1999 | Nippon Rinsho | pmid:10036951 |
| Yang JC et al. | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. | 1999 | J Microbiol Immunol Infect | pmid:11561564 |
| Nakagawa M et al. | [A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer]. | 1999 | Nippon Rinsho | pmid:10036952 |
| Kihira K et al. | [Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections]. | 1999 | Nippon Rinsho | pmid:10036953 |
| Goto T et al. | [Erosive duodenitis after eradication therapy for Helicobacter pylori]. | 1999 | Nihon Shokakibyo Gakkai Zasshi | pmid:10047687 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Gilljam M et al. | Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. | 1999 | Eur. Respir. J. | pmid:10515412 |
| Mach T and Zahradnik-Bilska J | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. | 1999 | Prz. Lek. | pmid:10575912 |
| Rovira E et al. | Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. | 1999 | Respiration | pmid:10516537 |
| Dionisio D et al. | Encephalitis caused directly by Mycoplasma pneumoniae. | 1999 | Scand. J. Infect. Dis. | pmid:10576133 |
| Huchon G | How to manage the low-risk patient with lower respiratory tract infection? | 1999 | Respiration | pmid:10577170 |
| Foster SF et al. | Chronic pneumonia caused by Mycobacterium thermoresistibile in a cat. | 1999 | J Small Anim Pract | pmid:10516950 |
| de Luis DA et al. | Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. | 1999 | Clin Nutr | pmid:10578022 |
| Goldberg EI et al. | Henoch-Schönlein purpura induced by clarithromycin. | 1999 | Int. J. Dermatol. | pmid:10517691 |
| Tanigawara Y et al. | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. | 1999 | Clin. Pharmacol. Ther. | pmid:10579481 |
| Tomioka H et al. | Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 | Antimicrob. Agents Chemother. | pmid:10582897 |
| Komatsu H et al. | Mycobacterium avium infection of the skin associated with lichen scrofulosorum: report of three cases. | 1999 | Br. J. Dermatol. | pmid:10583068 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Hoshi T et al. | Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori--a comparison before and after H pylori eradication in non-atrophic gastritis. | 1999 | Hum. Pathol. | pmid:10667417 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Keiser P et al. | A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection. | 1999 | Int J STD AIDS | pmid:10639059 |
| Gschwantler M et al. | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468682 |
| Paré P et al. | Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468683 |
| Yatsunami J et al. | Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. | 1999 | Cancer Lett. | pmid:10660084 |
| Sung JJ et al. | One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468684 |
| Catalano F et al. | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. | 1999 | Helicobacter | pmid:10469192 |
| Yoshida Y et al. | Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. | 1999 | Bioorg. Med. Chem. Lett. | pmid:10560737 |
| Boyanova L et al. | Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. | 1999 | Diagn. Microbiol. Infect. Dis. | pmid:10459482 |
| Sendi PP et al. | Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. | 1999 | J Eval Clin Pract | pmid:10461580 |
| Kamada T et al. | Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. | 1999 | Helicobacter | pmid:10469195 |
| Valencia IC et al. | Disseminated cutaneous Mycobacterium chelonae infection after injection of bovine embryonic cells. | 1999 | Int. J. Dermatol. | pmid:10561050 |
| Szlachcic A et al. | Helicobacter pylori and its eradication in rosacea. | 1999 | J. Physiol. Pharmacol. | pmid:10695558 |
| Lind T et al. | The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. | 1999 | Gastroenterology | pmid:9922303 |
| MartÃn de Argila C and Boixeda D | [A ration proposal for the eradicating treatment of Helicobacter pylori infection]. | 1999 | Med Clin (Barc) | pmid:10562929 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Kuipers EJ and Klinkenberg-Knol EC | Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. | 1999 | Gastroenterology | pmid:9922329 |
| Tanaka E et al. | Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. | 1999 | Am. J. Respir. Crit. Care Med. | pmid:10471610 |
| Adeyemi EO et al. | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. | 1999 | Eur J Gastroenterol Hepatol | pmid:10563537 |
| Klapper SR and Patrinely JR | Periocular atypical mycobacterial infections. | 1999 | Ophthalmology | pmid:10485521 |
| Matsuoka M et al. | Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. | 1999 | Gut | pmid:10486356 |
| Tyagi AK et al. | An unreported side effect of topical clarithromycin when used successfully to treat Mycobacterium avium-intracellulare keratitis. | 1999 | Cornea | pmid:10487437 |
| RodrÃguez Téllez M et al. | Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. | 1999 | Rev Esp Enferm Dig | pmid:10491487 |
| Gutiérrez-Cabano CA and Raynald AC | Gastroprotective effect of intragastric clarithromycin against damage induced by ethanol in rats. | 1999 | Dig. Dis. Sci. | pmid:10492159 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
| Pandita D and Carson PJ | Thyroid abscess caused by Mycobacterium chelonae. | 1999 | Clin. Infect. Dis. | pmid:10452671 |
| Härtig G et al. | [Symptomatic psychosis in bland sinus thrombosis and antibiotic therapy]. | 1999 | Psychiatr Prax | pmid:10457975 |
| Labenz J and Stolte M | [Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?]. | 1999 | Z Gastroenterol | pmid:10458014 |
| Bazzoli F | My approach to Helicobacter pylori eradication. | 1999 | Eur J Gastroenterol Hepatol | pmid:10443911 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Hewitt RG et al. | Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. | 1999 | AIDS | pmid:10449290 |
| Enroth H et al. | Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. | 1999 | Clin. Infect. Dis. | pmid:10451171 |
| Anzueto A et al. | The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. | 1999 | Clin. Infect. Dis. | pmid:10451195 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Hoellman DB et al. | Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. | 1999 | J. Antimicrob. Chemother. | pmid:10382885 |
| Huang J and Hunt RH | The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383500 |
| Miwa H et al. | Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383502 |
| Ducóns JA et al. | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383507 |
| Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
| Sonnenberg A et al. | Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. | 1999 | Am J Manag Care | pmid:10345967 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Kashimura H et al. | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215732 |
| Debets-Ossenkopp YJ et al. | Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. | 1999 | J. Antimicrob. Chemother. | pmid:10350380 |
| Lee JM et al. | Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215733 |
| Neville PM et al. | The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215734 |
| Hoffman JS et al. | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215735 |
| Abbott GW et al. | MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. | 1999 | Cell | pmid:10219239 |
| van der Hulst RW et al. | [Treatment of Helicobacter pylori infections]. | 1999 | Ned Tijdschr Geneeskd | pmid:10221109 |
| Stewart AK et al. | Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. | 1999 | Blood | pmid:10391696 |
| Tsukamoto T et al. | Biofilm in complicated urinary tract infection. | 1999 | Int. J. Antimicrob. Agents | pmid:10394976 |
| Alvarez-Elcoro S and Enzler MJ | The macrolides: erythromycin, clarithromycin, and azithromycin. | 1999 | Mayo Clin. Proc. | pmid:10377939 |
| Hafner R et al. | Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. | 1999 | J. Infect. Dis. | pmid:10395860 |
| Miwa H et al. | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. | 1999 | J. Gastroenterol. Hepatol. | pmid:10207779 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
| Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
| Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
| Xiao SD et al. | High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102963 |
| Liu WZ et al. | Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102964 |
| Huang J and Hunt RH | Clarithromycin-based triple therapies. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102978 |
| Lindeboom JA et al. | Clarithromycin as a single-modality treatment in mycobacterial avium-intracellular infections. | 1999 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:9927080 |
| Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
| Carbon C and Poole MD | The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. | 1999 | J Chemother | pmid:10326741 |
| Moore PA | Dental therapeutic indications for the newer long-acting macrolide antibiotics. | 1999 | J Am Dent Assoc | pmid:10492541 |
| Horgan SE et al. | Use of a low nutrient culture medium for the identification of bacteria causing severe ocular infection. | 1999 | J. Med. Microbiol. | pmid:10403423 |
| Nilsson F and Walder M | [Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance]. | 1999 | Lakartidningen | pmid:10064930 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |
| Sato K and Tomioka H | [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo]. | 1999 | Kekkaku | pmid:10067057 |
| Schultz-Süchting F et al. | Treatment of Helicobacter heilmannii-associated gastritis in a 14-year-old boy. | 1999 | J. Pediatr. Gastroenterol. Nutr. | pmid:10067743 |
| Vásconez C et al. | Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. | 1999 | J. Hepatol. | pmid:10068106 |
| Fraser AG et al. | Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. | 1999 | Aust N Z J Med | pmid:10868529 |
| Yajima T et al. | Optimum spray congealing conditions for masking the bitter taste of clarithromycin in wax matrix. | 1999 | Chem. Pharm. Bull. | pmid:10071855 |